Last updated: February 20, 2026
Zileuton is a leukotriene synthesis inhibitor primarily used to prevent asthma symptoms. It is marketed under the brand name Zyflo by Abbott Laboratories and is available in both immediate-release and controlled-release formulations. The drug functions by inhibiting 5-lipoxygenase, reducing leukotriene production.
Manufacturing and Supply Chain Overview
Originator and Key Manufacturers
Abbott Laboratories holds the original patent and marketed Zileuton. As of 2023, Abbott is the primary supplier of Zyflo. The patent expired in 2017, leading to generic manufacturing.
Generic Manufacturers
Following patent expiration, multiple generic pharmaceutical companies now produce Zileuton. These companies include:
| Company |
Geographical Market Availability |
Formulations Available |
Approximate Market Entry Year |
| Mylan (now part of Viatris) |
Global |
Immediate-release and controlled-release |
2017 |
| Teva Pharmaceutical Industries |
Global |
Immediate-release |
2018 |
| SUN Pharmaceutical Industries |
Selected Markets |
Immediate-release |
2019 |
| Cipla |
Selected Markets |
Immediate-release |
2018 |
Supply Chain Dynamics
- Raw Materials: The active pharmaceutical ingredient (API), zileuton, is synthesized using complex processes involving phenolic intermediates and specific oxidation steps. Key raw materials are sourced from specialized chemical suppliers.
- API Manufacturing: API synthesis occurs largely in India, China, and Europe, with a small number of manufacturers due to the complexity of synthesis.
- Formulation and Packaging: Finished formulations are produced in facilities that comply with Good Manufacturing Practice (GMP), primarily in North America and India.
Major API Suppliers
| Company |
Location |
API Production Capacity |
Notes |
| Zhejiang Hisun Pharmaceuticals |
China |
Estimated at 50-100 kg/month |
Key API supplier for generics |
| SAFC Pharma (part of Merck) |
USA |
Limited, based on demand |
Selective API manufacturing |
| Synthesis companies in India |
India |
Varies, multiple vendors |
API sourced via multiple suppliers |
Regulatory Impact
- FDA Approvals: Generic suppliers obtained ANDA (Abbreviated New Drug Application) approvals post-2017.
- Market Approvals: Different markets may have varying approval statuses; Europe’s EMA has approved generics since 2018.
Supply Disruptions and Risks
- The specialized synthesis routes increase reliance on specific suppliers or regions, particularly China and India.
- Political, trade, or regulatory changes could impact supply stability.
- COVID-19 affected global supply chains, causing temporary shortages in raw materials and finished products.
Pricing and Market Trends
- Prices of generic Zileuton have decreased approximately 50-70% since patent expiry.
- Market competition has led to price stabilization in most regions.
- Supply disruptions could lead to price volatility temporarily.
Key Distribution Points
- Major pharmacies and hospital procurement systems rely on these suppliers.
- Wholesale distributors maintain inventories from multiple manufacturers to mitigate supply disruptions.
Conclusion
The primary suppliers of zileuton include Abbott Laboratories (original patent holder), with additional production by multiple generic companies such as Mylan (Viatris), Teva, and Cipla. The API is predominantly produced in China and India, with formulations manufactured globally. Supply chain stability depends on geopolitical and regulatory factors, along with raw material availability.
Key Takeaways
- Abbott remains the only original manufacturer; generics dominate post-2017.
- Major API sources are in China and India, with multiple formulators globally.
- Supply chain risks include geopolitical issues, raw material sourcing, and pandemic-related disruptions.
- Price competition has reduced costs, increasing accessibility.
- Regulatory approval varies by region, impacting market penetration.
FAQs
Q1: Who are the main generic suppliers of zileuton?
A1: Mylan (Viatris), Teva, Sun Pharmaceutical Industries, and Cipla are among the key generic manufacturers.
Q2: Where is the zileuton API primarily produced?
A2: The API is mainly manufactured in China and India, with some production in Europe and the USA.
Q3: How has patent expiration affected the market?
A3: It has increased the number of suppliers and reduced drug prices, improving access.
Q4: Are there supply chain concerns for zileuton?
A4: Yes, reliance on specific regions for raw materials poses risks like political instability and COVID-19 impacts.
Q5: What regulatory bodies approve generic zileuton?
A5: The FDA approves generics in the US; EMA oversees approval in Europe. Other regions have local regulatory authorities.
References
- U.S. Food and Drug Administration. (2022). ANDA approvals and drug information. https://www.fda.gov/drugs/under-review-new-drug-application-andat-approvals
- European Medicines Agency. (2021). Zileuton drug approvals. https://www.ema.europa.eu/en/medicines/human/EPAR
- Pharma Intelligence. (2020). API supply dynamics in China and India. https://pharmaintelligence.com/news/api-supply-chains-shift
- IQVIA. (2022). Global generic drug market trends. https://www.iqvia.com/insights/the-iqvia-institute/market-trends
- Drugs.com. (2023). Zileuton product details and suppliers. https://www.drugs.com/international/zileuton.html
